Cited by 2,770Cancer Cells and MetastasisDrug Transport and Resistance MechanismsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 183 of the 188 references it cites were found in a registry or an index.

A view on drug resistance in cancer

Open access

Vasan, Neil, Baselga, José, Hyman, David M.·2019·Nature

DOI 10.1038/s41586-019-1730-1PMC PMC8008476

Open this paper in CoChat — free account Open PDF

Abstract

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1730-1

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Show all 188 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 301–400 of 1,001

2-Aminobenzothiazoles in anticancer drug design and discovery
Huang, G., Cierpicki, T., & Grembecka, J. E. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106477 · Cited by 60
Dual-Stimuli-Responsive Nanotheranostics for Dual-Targeting Photothermal-Enhanced Chemotherapy of Tumor
He, T., He, J., Younis, M. R., Blum, N. T., Lei, S., Zhang, Y., Huang, P., & Lin, J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c03211 · Cited by 56
Pomegranate: A promising avenue against the most common chronic diseases and their associated risk factors (Review)
Lavoro, A., Falzone, L., Gattuso, G., Salemi, R., Cultrera, G., Leone, G. M., Scandurra, G., Candido, S., & Libra, M. (2021) · International Journal of Functional Nutrition · doi:10.3892/ijfn.2021.16 · Cited by 55
Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions
Hosea, R., Hillary, S., Wu, S., & Kasim, V. (2023) · Cancers · doi:10.3390/cancers15133506 · Cited by 57
Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review
Sharma, N. K., Bahot, A., Sekar, G., Bansode, M., Khunteta, K., Sonar, P. V., Hebale, A., Salokhe, V., & Sinha, B. K. (2024) · Cancers · doi:10.3390/cancers16040680 · Cited by 56
Photodynamic Therapy Induced Mitochondrial Targeting Strategies for Cancer Treatment: Emerging Trends and Insights
Desai, V. M., Choudhary, M., Chowdhury, R., & Singhvi, G. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01185 · Cited by 55
Decoding the interplay between genetic and non-genetic drivers of metastasis
Karras, P., Black, J. R., McGranahan, N., & Marine, J. (2024) · Nature · doi:10.1038/s41586-024-07302-6 · Cited by 60
Direct targeting of HSP90 with daurisoline destabilizes β-catenin to suppress lung cancer tumorigenesis
Huang, X., Yan, X., Zhang, Q., Hong, P., Zhang, W., Liu, Y.-P., Xu, W. W., Li, B., & He, Q. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.024 · Cited by 55
Circ_0011292 Enhances Paclitaxel Resistance in Non-Small Cell Lung Cancer by Regulating miR-379-5p/TRIM65 Axis
Guo, C., Wang, H., Jiang, H., Qiao, L., & Wang, X. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3546 · Cited by 55
The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis
Castro, R. A. D., Borrell, S., & Gagneux, S. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa071 · Cited by 56
The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications
Qin, S., Mao, Y., Wang, H., Duan, Y., & Zhao, L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60641 · Cited by 55
Spheroid Culture Differentially Affects Cancer Cell Sensitivity to Drugs in Melanoma and RCC Models
Filipiak-Duliban, A., Brodaczewska, K. K., Kajdasz, A., & Kiéda, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031166 · Cited by 59
Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation
Zhou, J., Tang, D., He, L., Lin, S., Lei, J. H., Sun, H., Xu, X., & Deng, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106830 · Cited by 54
Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer
Zeng, W., Zhang, R., Huang, P., Chen, M., Chen, H., Zeng, X., Liu, J., Zhang, J., Huang, D., & Lao, L. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1941 · Cited by 54
PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression
Wu, L., Cai, S., Deng, Y., Zhang, Z., Zhou, X.-H., Su, Y., & Xu, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107443 · Cited by 56
Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression
Ye, L., Li, Y., Zhang, S., Wang, J., & Lei, B. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.05.002 · Cited by 55
Drug resistance mechanisms in cancers: Execution of pro-survival strategies
Dhanyamraju, P. K. (2023) · Journal of Biomedical Research · doi:10.7555/jbr.37.20230248 · Cited by 56
ALYREF (Aly/REF export factor): A potential biomarker for predicting cancer occurrence and therapeutic efficacy
Zhao, Y., Xing, C., & Peng, H. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122372 · Cited by 54
RETRACTED ARTICLE: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Wang, H., Fleishman, J. S., Cheng, S., Wang, W., Wu, F., Wang, Y., & Wang, Y. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02088-7 · Cited by 56
Retracted
Acevaltrate as a novel ferroptosis inducer with dual targets of PCBP1/2 and GPX4 in colorectal cancer
Yu, D., Hu, H., Zhang, Q., Wang, C., Xu, M., Xu, H., Geng, X., Cai, M., Zhang, H., Guo, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02296-7 · Cited by 64
Ellagic Acid and Schisandrins: Natural Biaryl Polyphenols with Therapeutic Potential to Overcome Multidrug Resistance in Cancer
Yoganathan, S., Alagaratnam, A., Acharekar, N., & Kong, J. (2021) · Cells · doi:10.3390/cells10020458 · Cited by 54
Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)
Chen, Y. X., Yuan, X., Tang, M., Shi, M., Yang, T., Liu, K., Deng, D., & Chen, L. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105508 · Cited by 51
Nanomedicine tactics in cancer treatment: Challenge and hope
Zoubi, M. S. A., & Al‐Zoubi, R. M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103677 · Cited by 52
Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer
Xiao, Y., Yao, W., Lin, M., Huang, W., Li, B., Peng, B., Ma, Q., Zhou, X., & Liang, M. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2079769 · Cited by 52
ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts
Jiang, F., Jia, K., Chen, Y., Ji, C., Chong, X., Li, Z., Zhao, F., Bai, Y., Ge, S., Gao, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202300881 · Cited by 52
Targeting Glucose Metabolism in Cancer Cells as an Approach to Overcoming Drug Resistance
Cunha, A., Silva, P. M. A., Sarmento, B. F. C. C., & Queirós, O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112610 · Cited by 59
Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling
Lee, J.-S., Lee, H., Jang, H., Woo, S. M., Park, J. B., Lee, S.-H., Kang, J. H., Kim, H. Y., Song, J., & Kim, S. (2020) · Cells · doi:10.3390/cells9092013 · Cited by 52
Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
Dhuguru, J., & Ghoneim, O. (2022) · Molecules · doi:10.3390/molecules27072294 · Cited by 53
NIR‐II Emissive Ru(II) Metallacycle Assisting Fluorescence Imaging and Cancer Therapy
Fan, Y., Li, C., Bai, S., Ma, X., Yang, J., Guan, X., & Sun, Y. (2022) · Small · doi:10.1002/smll.202201625 · Cited by 51
Selectively down-regulated PD-L1 by albumin-phenformin nanoparticles mediated mitochondrial dysfunction to stimulate tumor-specific immunological response for enhanced mild-temperature photothermal efficacy
Zhou, Z., Jiang, N., Chen, J., Zheng, C., Guo, Y., Ye, R., Qi, R., & Shen, J. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01124-8 · Cited by 51
A Cyclometalated Ruthenium(II) Complex Induces Oncosis for Synergistic Activation of Innate and Adaptive Immunity
Feng, T., Tang, Z., Shu, J., Wu, X., Jiang, H., Chen, Z., Chen, Y., Ji, L., & Chao, H. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202405679 · Cited by 52
Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy
Zang, C., Tian, Y., Tang, Y., Tang, M., Yang, D., Chen, F., Ghaffarlou, M., Tu, Y., Ashrafizadeh, M., & Yan, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05490-3 · Cited by 54
Development of PROTAC Degrader Drugs for Cancer
Vetma, V., O’Connor, S., & Ciulli, A. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061824-105806 · Cited by 55
Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance
Xiao, Y., Hassani, M., Moghaddam, M. B., Fazilat, A., Ojarudi, M., & Valilo, M. (2025) · Medical Oncology · doi:10.1007/s12032-025-02675-8 · Cited by 58
Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery
Chen, Y., Sun, H., Li, Y., Han, X., Yang, Y., Chen, Z., Zhao, X., Qian, Y., Liu, X., Zhou, F., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.07.033 · Cited by 55
EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets
Jiang, M., Wang, J., Li, Y., Zhang, K., Wang, T., Bo, Z., Lu, S., Alarcón, R., Wei, R., Zhu, M., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101276 · Cited by 57
Hypoxia induces chemoresistance of esophageal cancer cells to cisplatin through regulating the lncRNA-EMS/miR-758-3p/WTAP axis
Zhu, Z., Pang, Y., Jin, G., Zhang, H., Wang, W., Liu, J.-W., Tuo, G., Wu, P., Yang, Y., Wang, Z.-Q., et al. (2021) · Aging · doi:10.18632/aging.203062 · Cited by 51
Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay
Cosentino, G., Plantamura, I., Tagliabue, E., Iorio, M. V., & Cataldo, A. (2021) · Cancers · doi:10.3390/cancers13153691 · Cited by 52
Cycloruthenated Self‐Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers
Li, J., Zeng, L., Wang, Z., Chen, H., Fang, S., Wang, J., Cai, C., Xing, E., Liao, X., Li, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100245 · Cited by 50
Recent Progress in Small Spirocyclic, Xanthene-Based Fluorescent Probes
Keller, S., Kamiya, M., & Urano, Y. (2020) · Molecules · doi:10.3390/molecules25245964 · Cited by 51
An injectable and biodegradable nano-photothermal DNA hydrogel enhances penetration and efficacy of tumor therapy
Zhou, L., Pi, W., Hao, M., Li, Y., An, H., Li, Q., Zhang, P., & Wen, Y. (2021) · Biomaterials Science · doi:10.1039/d1bm00568e · Cited by 49
Stepwise responsive carboxymethyl chitosan-based nanoplatform for effective drug-resistant breast cancer suppression
Peng, H., Qiao, L., Shan, G., Gao, M., Zhang, R., Yi, X., & He, X. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119554 · Cited by 51
NF-κB in Cell Deaths, Therapeutic Resistance and Nanotherapy of Tumors: Recent Advances
Wu, X., Sun, L., & Xu, F. (2023) · Pharmaceuticals · doi:10.3390/ph16060783 · Cited by 51
Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma via miR-876-3p
Kang, S. H., Oh, S. Y., Lee, K.-Y., Lee, H., Kim, M.-S., Kwon, T., Kim, J., Lee, S., Choi, S., & Hong, S. (2023) · Theranostics · doi:10.7150/thno.87329 · Cited by 50
Tumor microbiome: roles in tumor initiation, progression, and therapy
Zhang, S., Huang, J., Jiang, Z., Tong, H., Ma, X., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00248-9 · Cited by 58
Ultrasmall Ag2Te Quantum Dots with Rapid Clearance for Amplified Computed Tomography Imaging and Augmented Photonic Tumor Hyperthermia
Dong, L., Li, W., Yu, L., Sun, L., Chen, Y., & Hong, G. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c12948 · Cited by 50
Bioresponsive prodrug nanogel-based polycondensate strategy deepens tumor penetration and potentiates oxidative stress
Ma, X., Zhang, T., Qiu, W., Liang, M., Gao, Y., Xue, P., Kang, Y., & Xu, Z. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.127657 · Cited by 49
Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies
Taghour, M. S., Elkady, H., Eldehna, W. M., El‐Deeb, N. M., Kenawy, A. M. A., El-Wahab, A. E. A., Elkaeed, E. B., Alsfouk, B. A. A., Metwaly, A. M., & Eissa, I. H. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2164356 · Cited by 49
Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
Jiang, L., Li, L., Liu, Y., Zhan, M., Lu, L., Yuan, S., & Liu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1097277 · Cited by 50
Smart composite scaffold to synchronize magnetic hyperthermia and chemotherapy for efficient breast cancer therapy
Sun, R., Chen, H., Wang, M., Yoshitomi, T., Takeguchi, M., Kawazoe, N., Yang, Y., & Chen, G. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122511 · Cited by 49
Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality
Liu, F., Xin, M., Feng, H., Zhang, W., Liao, Z., Sheng, T., Wen, P., Wu, Q., Liang, T., Shi, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk8264 · Cited by 53
Chitosan- and hyaluronic acid-based nanoarchitectures in phototherapy: Combination cancer chemotherapy, immunotherapy and gene therapy
Wang, Z., Pang, S., Liu, X., Dong, Z., Tian, Y., Ashrafizadeh, M., Rabiee, N., Ertaş, Y. N., & Mao, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132579 · Cited by 49
Lactate-mediated lactylation in human health and diseases: Progress and remaining challenges
Hu, X., Wu, X., Xu, J., & Xu, X. M. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.11.010 · Cited by 51
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
Tang, L.-B., Peng, Y., Chen, J., Li, J.-T., Zheng, M.-M., Lv, W., Lu, C., Wei, X., Cai, D.-X., Guo, Z. J., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01029-7 · Cited by 49
Molecular avenues in targeted doxorubicin cancer therapy
Roychoudhury, S., Kumar, A., Bhatkar, D., & Sharma, N. K. (2020) · Future Oncology · doi:10.2217/fon-2019-0458 · Cited by 49
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment
de Porras, V. R., Wang, X. C., Palomero, L., Marín‐Aguilera, M., Solé-Blanch, C., Indacochea, A., Jiménez, N., Bystrup, S., Bakht, M. K., Conteduca, V., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.10.001 · Cited by 51
Reconstituted high density lipoprotein (rHDL), a versatile drug delivery nanoplatform for tumor targeted therapy
Mei, Y., Tang, L., Xiao, Q., Zhang, Z., Zhang, Z., Zang, J., Zhou, J., Wang, Y., Wang, W., & Ren, M. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb02139c · Cited by 52
Natural isoflavonoids in invasive cancer therapy: From bench to bedside
Cayetano‐Salazar, L., Olea‐Flores, M., Zuñiga‐Eulogio, M. D., Oppenheimer, C. W., Fernández‐Tilapa, G., Catalán, M. A. M., Zacapala-Gómez, A. E., Ortiz‐Ortiz, J., Ortuño‐Pineda, C., & Navarro‐Tito, N. (2021) · Phytotherapy Research · doi:10.1002/ptr.7072 · Cited by 49
Polymeric Encapsulation of a Ru(II)-Based Photosensitizer for Folate-Targeted Photodynamic Therapy of Drug Resistant Cancers
Karges, J., Tharaud, M., & Gasser, G. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02006 · Cited by 49
The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance
Ghazimoradi, M. H., & Babashah, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.966083 · Cited by 48
SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning
Preto, A. J., Matos‐Filipe, P., Mourão, J., & Moreira, I. S. (2022) · GigaScience · doi:10.1093/gigascience/giac087 · Cited by 55
Cervical extracellular matrix hydrogel optimizes tumor heterogeneity of cervical squamous cell carcinoma organoids
Song, H., Jiang, H., Hu, W., Hai, Y., Cai, Y., Li, H., Liao, Y. R., Huang, Y., Lv, X., Zhang, Y., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl3511 · Cited by 49
Nanomedicine solutions to intricate physiological-pathological barriers and molecular mechanisms of tumor multidrug resistance
Li, Y., & Xu, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.007 · Cited by 48
Synthesis of iridium-based nanocomposite with catalase activity for cancer phototherapy
Wu, H., Jiang, Q., Luo, K., Zhu, C., Xie, M., Wang, S., Fei, Z., & Zhao, J. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00948-8 · Cited by 48
Rationale design, synthesis, cytotoxicity evaluation, and in silico mechanistic studies of novel 1,2,3-triazoles with potential anticancer activity
Othman, E. M., Fayed, E. A., Husseiny, E. M., & Abulkhair, H. S. (2022) · New Journal of Chemistry · doi:10.1039/d2nj02061k · Cited by 48
Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response
Ebrahimi, N., Manavi, M. S., Faghihkhorasani, F., Fakhr, S. S., Baei, F. J., Khorasani, F. F., Zare, M. M., Far, N. P., Rezaei‐Tazangi, F., Ren, J. T., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10162-7 · Cited by 50
Exploring the Potential of Breast Microbiota as Biomarker for Breast Cancer and Therapeutic Response
Dieleman, S., Aarnoutse, R., Ziemons, J., Kooreman, L. F. S., Boleij, A., & Smidt, M. L. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.02.020 · Cited by 48
Emerging nanotaxanes for cancer therapy
Zhang, Y., Zhang, W., Wang, Y., Zhu, J., Zhou, M., Peng, C., He, Z., Sun, J., Li, Z., & Gui, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120790 · Cited by 48
Polyethyleneimine (PEI) as a Polymer-Based Co-Delivery System for Breast Cancer Therapy
Fahira, A. I., Amalia, R., Barliana, M. I., Gatera, V. A., & Abdulah, R. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s350403 · Cited by 46
Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer
Zhao, S., Pan, T., Deng, J., Cao, L., Vicencio, J. M., Liu, J., Zhou, G., Ng, T., & Zhang, J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02077-x · Cited by 47
Therapeutic challenges in peripheral T-cell lymphoma
Luan, Y., Li, X., Luan, Y., Luo, J.-Y., Dong, Q., Ye, S., Li, Y., Li, Y., Jia, L., Yang, J. J. J., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01904-w · Cited by 49
Molecular Mechanisms of Drug Resistance in Leishmania spp.
Moncada-Díaz, M. J., Rodríguez-Almonacid, C. C., Quiceno, E., Khuong, F. T. H., Muskus, C., & Karamysheva, Z. N. (2024) · Pathogens · doi:10.3390/pathogens13100835 · Cited by 47
Self‐Assembled Metal Complexes in Biomedical Research
Wang, W., Xu, Y., Tang, Y., & Li, Q. (2024) · Advanced Materials · doi:10.1002/adma.202416122 · Cited by 47
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Wei, J., Lu, M., Wei, T., Fleishman, J. S., Yu, H. J., Chen, X.-L., Kong, X.-T., Sun, S., Li, N., Yang, Y., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101229 · Cited by 53
Cytotoxicity of 4-substituted quinoline derivatives: Anticancer and antileishmanial potential
Costa, C. A., Lopes, R. D. M., Ferraz, L. S., Esteves, G. N. N., Iório, J. F. D., de Souza, A. A., de Oliveira, I. M., Manarin, F., Júdice, W. A. D. S., Stefani, H. A., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115511 · Cited by 46
Stem cell quiescence and its clinical relevance
Luo, M., Li, J.-F., Yang, Q., Zhang, K., Wang, Z., Zheng, S. S., & Zhou, J. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i11.1307 · Cited by 48
Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance
Khot, V. M., Salunkhe, A. B., Pricl, S., Bauer, J., Thorat, N. D., & Townley, H. E. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.016 · Cited by 47
Nanotechnology assisted photo- and sonodynamic therapy for overcoming drug resistance
Li, R., Chen, Z., Dai, Z., & Yu, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0328 · Cited by 45
AdipoRon and Other Adiponectin Receptor Agonists as Potential Candidates in Cancer Treatments
Nigro, E., Daniele, A., Salzillo, A., Ragone, A., Naviglio, S., & Sapio, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115569 · Cited by 46
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance
Chen, S., Zhao, Y., Liu, S., Zhang, J., Assaraf, Y. G., Cui, W., & Wang, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100821 · Cited by 47
Drug Resistance: An Incessant Fight against Evolutionary Strategies of Survival
Ramos‐Martín, F., & D’Amelio, N. (2023) · Microbiology Research · doi:10.3390/microbiolres14020037 · Cited by 51
Challenges and opportunities for improving the druggability of natural product: Why need drug delivery system?
Tang, P., Shen, T., Wang, H., Zhang, R., Zhang, X., Li, X., & Xiao, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114955 · Cited by 46
Powerful Synergy of Traditional Chinese Medicine and Aggregation-Induced Emission-Active Photosensitizer in Photodynamic Therapy
Sun, F., Shen, H., Liu, Q., Chen, Y., Guo, W., Du, W., Xu, C., Wang, B., Xing, G., Jin, Z., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04342 · Cited by 45
Targeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 51
Recent advances in electrospun nanofiber-based implantable drug delivery systems for breast cancer therapy
Xing, J., Feng, J., Wang, Q., Yu, D., & Bligh, S. W. A. (2026) · RSC Pharmaceutics · doi:10.1039/d5pm00265f · Cited by 48
Discovery of a Secalonic Acid Derivative from Aspergillus aculeatus , an Endophyte of Rosa damascena Mill., Triggers Apoptosis in MDA-MB-231 Triple Negative Breast Cancer Cells
Farooq, S., Qayum, A., Nalli, Y., Lauro, G., Chini, M. G., Bifulco, G., Chaubey, A., Singh, S. K., Riyaz‐Ul‐Hassan, S., & Ali, A. (2020) · ACS Omega · doi:10.1021/acsomega.0c02505 · Cited by 45
Poly (β‐amino esters) based potential drug delivery and targeting polymer; an overview and perspectives (review)
Iqbal, S., Qu, Y., Dong, Z., Zhao, J., Khan, A. R., Rehman, S., & Zhao, Z. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.110097 · Cited by 46
Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior
Dong, Z., Yan, S., Liu, B., Hao, Y., Lin, L., Chang, T., Sun, H., Wang, Y., Li, H., Wu, H., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00199 · Cited by 45
Oncogenic viruses and chemoresistance: What do we know?
Nahand, J. S., Rabiei, N., Fathazam, R., Taghizadieh, M., Ebrahimi, M. S., Mahjoubin‐Tehran, M., Baghi, H. B., Khatami, A., Abbasi‐Kolli, M., Mirzaei, H. R., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105730 · Cited by 45
Robust O2 Supplementation from a Trimetallic Nanozyme-Based Self-Sufficient Complementary System Synergistically Enhances the Starvation/Photothermal Therapy against Hypoxic Tumors
Wu, C., Hsu, Y.-H., Chen, Y., Yang, L., Tseng, S., Chen, W., Huang, C., & Wan, D. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c10656 · Cited by 45
Finely tunable NIR‐II organic scaffolds for fluorescence/photoacoustic duplex imaging–guided noninvasive photothermal therapy of glioblastoma
Song, Y., Tong, X., Han, Y., & Zhang, Q. (2025) · Aggregate · doi:10.1002/agt2.680 · Cited by 47
Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment
Shan, Y., Ni, Q., Zhang, Q., Zhang, M., Wei, B., Cheng, L., Zhong, C., Wang, X., Wang, Q., Liu, J., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.014 · Cited by 45
More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44
Composite Scaffolds of Gelatin and Fe3O4 Nanoparticles for Magnetic Hyperthermia‐Based Breast Cancer Treatment and Adipose Tissue Regeneration
Sun, R., Chen, H., Zheng, J., Yoshitomi, T., Kawazoe, N., Yang, Y., & Chen, G. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202604 · Cited by 44
The Battlefield of Chemotherapy in Pediatric Cancers
Bo, L., Wang, Y., Li, Y., Wurpel, J. N. D., Huang, Z., & Chen, Z. (2023) · Cancers · doi:10.3390/cancers15071963 · Cited by 44
Fabrication of AuPt heterostructured nanorings for enhanced synergistic radio-photothermal therapy
Luo, M., Zhu, X., Yang, H., Yan, L., Cai, R., Zhao, Y., & Tan, W. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101919 · Cited by 44
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability
Wu, P., Hong, S., Starenki, D., Oshima, K., Shao, H., Gestwicki, J. E., Tsai, S., & Park, J. (2020) · Oncogene · doi:10.1038/s41388-020-1285-5 · Cited by 44
Group Behavior and Emergence of Cancer Drug Resistance
Bhattacharya, S., Mohanty, A. R., Achuthan, S., Kotnala, S., Jolly, M. K., Kulkarni, P., & Salgia, R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.009 · Cited by 44
Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
Ciciarello, M., Corradi, G., Forte, D., Cavo, M., & Curti, A. (2021) · Cancers · doi:10.3390/cancers13215319 · Cited by 45

Authors: Vasan, N., Baselga, J., & Hyman, D. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Hyman, David M.
ORCID: Vasan, Neil
Hyman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-11-13
Volume: 575
Issue: 7782
Pages: 299-309
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1730-1
PMC: PMC8008476
OpenAlex: W2988773550
Cited by: 2,770
References: 188
Citations by year: 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
FWCI: 21.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Eli Lilly and Company
National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
MeSH terms: Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A view on drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks